PHATHOM PHARMACEUTICALS, INC. (PHAT): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHAT Stock Price Chart Interactive Chart >
PHAT Price/Volume Stats
|Current price||$12.36||52-week high||$19.95|
|Prev. close||$11.58||52-week low||$6.09|
|Day high||$13.44||Avg. volume||506,106|
|50-day MA||$9.85||Dividend yield||N/A|
|200-day MA||$9.76||Market Cap||514.44M|
PHATHOM PHARMACEUTICALS, INC. (PHAT) Company Bio
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
Most Popular Stories View All
PHAT Latest News Stream
|Loading, please wait...|
PHAT Latest Social Stream
View Full PHAT Social Stream
Latest PHAT News From Around the Web
Below are the latest news stories about PHATHOM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PHAT as an investment opportunity.
Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001)Data expected to provide the basis for future regulatory submission for vonoprazan as a daily treatment for patients with NERD, pending completion of 20-week safety extension periodOver 45 million people in the U.S. are estimated to have NERD, the largest subcategory of gastroesophageal reflux disease (GERD)
The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax
Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax are included in this Analyst Blog.
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
PHAT Price Returns